Regulatory T Cell Therapies Research Group
2022 Ooi Group
Group Head
Dr Joshua Ooi
Dr Joshua Ooi is an Al and Val Rosenstrauss Fellow at the School of Clinical Sciences. His laboratory focusses on generating autoantigen-specific regulatory T cells to treat autoimmune diseases.
During his PhD (2009) and post-doctoral training, Dr. Ooi showed that inflammatory T helper cells specific for self proteins (known as autoantigens) underlie the pathogenesis of autoimmune disease. Now, Dr. Ooi and his team are devising regulatory T cell based therapies that specifically switch off the autoantigen-specific inflammatory response.
His work has been published in the top journals including in PNAS, J Clin Invest and Nature; and he has received funding by the NHMRC, Rebecca Cooper Medical Research Foundation and the Lupus Research Alliance to develop these new and innovative therapies.
